Antitumour dendritic cell vaccination in a priming and boosting approach.

Details

Serval ID
serval:BIB_14F09B31BAF0
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Antitumour dendritic cell vaccination in a priming and boosting approach.
Journal
Nature reviews. Drug discovery
Author(s)
Harari A., Graciotti M., Bassani-Sternberg M., Kandalaft L.E.
ISSN
1474-1784 (Electronic)
ISSN-L
1474-1776
Publication state
Published
Issued date
09/2020
Peer-reviewed
Oui
Volume
19
Number
9
Pages
635-652
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Mobilizing antitumour immunity through vaccination potentially constitutes a powerful anticancer strategy but has not yet provided robust clinical benefits in large patient populations. Although major hurdles still exist, we believe that currently available strategies for vaccines that target dendritic cells or use them to present antitumour antigens could be integrated into existing clinical practice using prime-boost approaches. In the priming phase, these approaches capitalize on either standard treatment modalities to trigger in situ vaccination and release tumour antigens or vaccination with dendritic cells loaded with tumour lysates or patient-specific neoantigens. In a second boost phase, personalized synthetic vaccines specifically boost T cells that were triggered during the priming phase. This immunotherapy approach has been enabled by the substantial recent improvements in dendritic cell vaccines. In this Perspective, we discuss these improvements, highlight how the prime-boost approach can be translated into clinical practice and provide solutions for various anticipated hurdles.
Pubmed
Create date
17/08/2020 9:51
Last modification date
23/10/2020 5:23
Usage data